A bispecific antibody approach for the potential prophylactic treatment of inherited bleeding disorders
Open Access
- 8 February 2024
- journal article
- research article
- Published by Springer Nature in Nature Cardiovascular Research
- Vol. 3 (2) , 166-185
Abstract
Inherited bleeding disorders such as Glanzmann thrombasthenia (GT) lack prophylactic treatment options. As a result, serious bleeding episodes are treated acutely with blood product transfusions or frequent, repeated intravenous administration of recombinant activated coagulation factor VII (rFVIIa). Here we describe HMB-001, a bispecific antibody designed to bind and accumulate endogenous FVIIa and deliver it to sites of vascular injury by targeting it to the TREM (triggering receptor expressed on myeloid cells)-like transcript-1 (TLT-1) receptor that is selectively expressed on activated platelets. In healthy nonhuman primates, HMB-001 prolonged the half-life of endogenous FVIIa, resulting in its accumulation. Mouse bleeding studies confirmed antibody-mediated potentiation of FVIIa hemostatic activity by TLT-1 targeting. In ex vivo models of GT, HMB-001 localized FVIIa on activated platelets and potentiated fibrin-dependent platelet aggregation. Taken together, these results indicate that HMB-001 has the potential to offer subcutaneous prophylactic treatment to prevent bleeds in people with GT and other inherited bleeding disorders, with a low-frequency dosing regimen.Keywords
Funding Information
- Hemab Therapeutics ApS
This publication has 89 references indexed in Scilit:
- Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchangeProceedings of the National Academy of Sciences, 2013
- The first comprehensive and quantitative analysis of human platelet protein composition allows the comparative analysis of structural and functional pathwaysBlood, 2012
- Towards automated crystallographic structure refinement with phenix.refineActa Crystallographica Section D Structural Biology, 2012
- Recombinant human factor VIIa (rFVIIa) cleared principally by antithrombin following intravenous administration in hemophilia patientsJournal of Thrombosis and Haemostasis, 2010
- Dynamical view of membrane binding and complex formation of human factor VIIa and tissue factorJournal of Thrombosis and Haemostasis, 2010
- Features and development of CootActa Crystallographica Section D Structural Biology, 2010
- XDSActa Crystallographica Section D Structural Biology, 2010
- TREM-like transcript-1 protects against inflammation-associated hemorrhage by facilitating platelet aggregation in mice and humansJournal of Clinical Investigation, 2009
- Phasercrystallographic softwareJournal of Applied Crystallography, 2007
- A TREM family member, TLT-1, is found exclusively in the α-granules of megakaryocytes and plateletsBlood, 2004